Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: early-phase trial registry
2 of 2 indexed Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements: 2 US clinical trials tracked, 2 recruiting.
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Joseph Tuscano, running 1 of these trials.
Enrollment posture brief
Registry condition recurrent-high-grade-b-cell-lymphoma-with-myc-and-bcl2-rearrangements
OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
NCT06834373
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Joseph Tuscano
NCT06905509
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Joseph Tuscano sponsors the most Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements trials on record, review their full trial history before evaluating a specific study. See Joseph Tuscano's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements condition card totals 2 registered trials; most-linked intervention Autologous Hematopoietic Stem Cell Transplantation; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.